Peptides

Taldefgrobep alfa

An engineered myostatin-binding protein with negative functional results in muscular-dystrophy development and an unsuccessful overall SMA primary endpoint.

Primary DMD development report plus sponsor-reported SMA result; investigational

Also known as: Taldefgrobep · BMS-986089 · RO7239361

Practical use

Evidence interpretation and clinical context

Start with the overall endpoint: State the failed primary analysis before discussing favorable subgroups.
Distinguish sponsors from publications: Label company updates as company reports and keep them separate from peer-reviewed primary results.
Track the actual development question: A new obesity trial asks a new question; a muscular-disease result does not answer it.

The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy.

The later SMA result — primary or official source

Current development context — primary or official source

Overview

Taldefgrobep alfa is a recombinant Adnectin protein designed to bind myostatin. Target suppression and muscle-volume changes were observed during development, but those biological findings did not consistently translate into better function.

Risks and limitations

The published DMD program reported no treatment-related safety withdrawals, but that observation does not establish safety for healthy use. Longer-term and population-specific risks remain separate from whether the target was suppressed.

How to read this

This program is useful for understanding why a successful laboratory or biomarker result can coexist with an unsuccessful clinical trial.

Research explained

The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy.

Who was studied

A primary report combining a healthy-volunteer phase 1 study and two randomized trials in ambulatory boys with DMD.

What was found

Free myostatin was strongly suppressed, with modest muscle or lean-mass effects. The phase 2/3 functional result failed its prespecified futility threshold, and the DMD program ended in 2019.

What it cannot establish

Three reported trials are not three independent successes. Target engagement and volume changes did not establish the intended functional improvement.

Read the original study

The later SMA result

Biohaven reported that RESILIENT did not significantly separate from placebo on the overall MFM-32 primary endpoint. Favorable subgroup or within-group changes should retain that qualification. This is a sponsor report, not an independent replication.

Supporting source

Current development context

Biohaven’s current pipeline identifies taldefgrobep as an investigational protein for obesity. A continuing program does not establish an approved treatment or overcome the earlier negative results by itself.

Supporting source